icrucumab icrucumab icrucumab (imc-18f1) is a human monoclonal antibody designed for the treatment of solid tumors. icrucumabmonoclonal antibodytypewhole antibodysourcehumantargetvegfr-1clinical dataother namesimc-18f1atc codenoneidentifierscas number1024603-92-6 nchemspidernoneuniit7h0b1r64ukeggd09926chemical and physical dataformulac6514h10024n1756o2032s42molar mass146796.63 g·mol−1 ny (what is this?) (verify) icrucumab was developed by imclone systems inc. it is undergoing phase i trials.